Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remodulin in critical limb ischemia
NCT00060996Phase 3Terminated
- Sponsor
- United Therapeutics Corporation
- Start
- Feb 2003
- Primary completion
- Sep 2004
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of treprostinil in critical limb ischemia (CLI) (3 arms), sponsored by United Therapeutics Corporation. Primary endpoint: Safety of continuous and daily subcutaneous Remodulin therapy at 12 weeks. Started Feb 2003; status: terminated.
02
Drugs
treprostinil
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT00060996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00060996.